These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35854405)

  • 21. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
    Hubbard H; Lawitz E
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Turnes J; Rincón D; Calleja JL; Delgado MB; Rosales JM; Andrade RJ; Manzano ML; Salmerón FJ; López MA; Calvo M; Gómez J; Molina E; Frias YN; Gálvez-Fernández RM; Vallejo-Senra N; París S; Santos de Lamadrid R; Olveira A
    Gastroenterol Hepatol; 2022 May; 45(5):342-349. PubMed ID: 34129903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    Martin MT; Patel S; Kulik L; Chan C
    J Hepatol; 2021 Jul; 75(1):251-254. PubMed ID: 33652031
    [No Abstract]   [Full Text] [Related]  

  • 24. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
    Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
    Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
    Kaba A; Yamanaga S; Hidaka Y; Toyoda M; Kashima M; Takekuma Y; Inadome A; Yokomizo H; Miyata A
    Transplant Proc; 2022 Mar; 54(2):549-551. PubMed ID: 35120765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
    Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
    BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    Dietz J; Sarrazin C
    J Hepatol; 2021 Jul; 75(1):254-255. PubMed ID: 33892009
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
    Hatanaka T; Kakizaki S; Kaburagi T; Saito N; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Yoshinaga T; Kashiwabara K; Naganuma A; Yamazaki Y; Uraoka T; Nagashima S; Takahashi M; Nishizawa T; Murata K; Okamoto H
    Intern Med; 2022 May; 61(10):1537-1543. PubMed ID: 34897154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
    Zhang Y; Jiang X; Zhao Y; Xu Y
    J Viral Hepat; 2021 Jan; 28(1):177-185. PubMed ID: 32961624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
    Reyentovich A; Gidea CG; Smith D; Lonze B; Kon Z; Fargnoli A; Pavone J; Rao S; Saraon T; Lewis T; Qian Y; Jacobson I; Moazami N
    Clin Transplant; 2020 Sep; 34(9):e13989. PubMed ID: 32441413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
    Shah R; Barclay ST; Peters ES; Fox R; Gunson R; Bradley-Stewart A; Shepherd SJ; MacLean A; Tong L; van Vliet VJE; Ngan Chiu Bong M; Filipe A; Thomson EC; Davis C
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia".
    Yu ML; Kao JH
    J Formos Med Assoc; 2021 Jun; 120(6):1410-1411. PubMed ID: 33422401
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
    Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
    J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
    J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
    Klinker H; Naumann U; Rössle M; Berg T; Bondin M; Lohmann K; Koenig B; Zeuzem S; Cornberg M
    Liver Int; 2021 Jul; 41(7):1518-1522. PubMed ID: 33966349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
    Hara T; Ohara T; Taniguchi M; Sakai H; Oka K; Iwai N; Tsuji T; Okuda T; Nagata A; Komaki T; Sakagami J; Kagawa K
    Intern Med; 2021 Aug; 60(15):2437-2443. PubMed ID: 33612683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
    Cotter TG; Jensen DM
    Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
    Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
    [No Abstract]   [Full Text] [Related]  

  • 40. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.